Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



3 Stocks to Rule the Next Decade of Diabetes Treatments

Diabetes is a huge threat to the world's health. More than 330 million people around the world are estimated to have suffered from the disease in 2011, and more than 550 million are expected to suffer from it by 2030. However, where there's a big problem, big pharma has a big solution. For Merck (NYSE: MRK  ) , Sanofi (NYSE: SNY  ) , and Novo Nordisk (NYSE: NVO  ) , treating diabetes has become a cash-generating windfall.

These three companies boast three of the top drugs for treating diabetes around the world, from Merck's strong Januvia to Sanofi's timeless Lantus. However, patent expirations and tough competition are making the diabetes field as competitive a market as any in big pharma. How will these three giants fare in the next 10 years for treating the world's fastest-growing health crisis?

In the video below, Fool contributor Dan Carroll tells you how these three big pharma kings dominate diabetes treatment -- and how they're poised to continue their reigns for another decade to come.

How you can find health care's next star stock
How can you unearth the next breakout health care company that will light up Wall Street and deliver a windfall for investors? Look for companies that shun the status quo and instead discover revolutionary, groundbreaking health care technologies. In The Motley Fool's brand-new FREE report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.

Read/Post Comments (1) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On October 20, 2013, at 6:08 AM, DrDiag wrote:

    Since the Albert Einstein Medical College clinical trial in which Biotivia Transmax was shown to prevent pre-diabetes from evolving into Type 2 Diabetes, and several subsequent human trials which confirm that Transmax reduces blood glucose levels, blood pressure and body weight, used both alone or in combination with the traditional Diabetes treatments such as Metformin, this company has become the default producer of Transmax Resveratrol. This compound has enormous potential as both a preventative and treatment for Diabetes.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2689307, ~/Articles/ArticleHandler.aspx, 9/25/2016 5:05:27 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 1 day ago Sponsored by:
DOW 18,261.45 -131.01 -0.71%
S&P 500 2,164.69 -12.49 -0.57%
NASD 5,305.75 -33.78 -0.63%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/23/2016 4:00 PM
MRK $62.96 Down -0.06 -0.10%
Merck and Co. CAPS Rating: ****
NVO $44.88 Down -0.69 -1.51%
Novo Nordisk CAPS Rating: *****
SNY $38.35 Down -0.22 -0.57%
Sanofi CAPS Rating: *****
JNJ $118.81 Down -0.65 -0.54%
Johnson and Johnso… CAPS Rating: *****